<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJNS</journal-id><journal-title-group><journal-title>World Journal of Neuroscience</journal-title></journal-title-group><issn pub-type="epub">2162-2000</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjns.2024.141006</article-id><article-id pub-id-type="publisher-id">WJNS-131517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Clinical and Therapeutic Aspects of Migraine in Brazzaville
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Motoula</surname><given-names>Latou Happhia Dinah Boubayi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Josue</surname><given-names>Diatewa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Prince</surname><given-names>Eliot Galieni Sounga Bandzouzi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ghislain</surname><given-names>Armel Mpandzou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Héloïse</surname><given-names>Stéphanie Ongoly Ikora</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karen</surname><given-names>Lise Obondzo Aloba</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Paul</surname><given-names>Macaire Ossou-Nguiet</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Neurology, Brazzaville University Hospital, Brazzaville, The Republic of the Congo</addr-line></aff><aff id="aff1"><addr-line>Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, The Republic of the Congo</addr-line></aff><aff id="aff3"><addr-line>Department of Neurology, Loandjili General Hospital, Pointe-Noire, The Republic of the Congo</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>01</month><year>2024</year></pub-date><volume>14</volume><issue>01</issue><fpage>56</fpage><lpage>71</lpage><history><date date-type="received"><day>16,</day>	<month>November</month>	<year>2023</year></date><date date-type="rev-recd"><day>26,</day>	<month>February</month>	<year>2024</year>	</date><date date-type="accepted"><day>29,</day>	<month>February</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Introduction:</b>
   Migraine is the most common primary headache, and can cause significant disability. There are two types, migraine without aura and migraine with aura. The diagnosis of migraine is essentially clinical. Worldwide prevalence was estimated at 11.6% in 2009. In Africa, it is estimated at 10.4%. <b>Objective: </b>To describe the clinical and therapeutic aspects of migraine in Brazzaville. <b>Patients</b> <b>and</b> <b>Methods:</b> This was a door-to-door cross-sectional study conducted from 1
  <sup>st</sup>
   May to 1
  <sup> st</sup>
   July 2018 in the city of Brazzaville. Subjects over 18 with clearly expressed consent were included. The questionnaire covered demographic characteristics, diagnostic criteria for migraine according to the IHS, treatments taken. The degree of disability was determined using the Migraine Disability Assessment Scale (MIDAS). Statistical analysis was performed using SPSS 22.0 for MAC. <b>Results</b>: Of the 1017 subjects interviewed in this study, 115 (39.9%) had migraine, including 73 women (63.47%) and 42 men (36.52%). In the group of migraine sufferers, the number of cases of definite migraine was 61 (53.04%) and that of probable migraine 54 (46.95%). For 81 migraine sufferers (70.43%), stress was the triggering factor. The frequency of attacks was weekly and monthly for 30 (26.1%) and 19 (16.5%) sufferers respectively. The location of the migraine was unilateral in 38% of cases and tilted in 24.3%. The intensity of the attack was described as moderate and severe in 41.7% and 57.4% of subjects respectively. Phonophobia/photophobia accompanied the migraine in 65.2% of cases. One hundred and eight subjects were treated. Of these, 106 (98.1%) were on medication. Eleven (10.37%) had received a medical prescription, and ninety-seven (89.8%) were self-medicating. Five and three subjects were under the care of a general practitioner and a neurologist respectively. <b>Conclusion</b>: Migraine is a frequent pathology in Brazzaville. Its preponderance among young people and women calls for the implementation of effective prevention strategies for these already vulnerable social groups. The form without aura was the most common type. Visual aura was the most common type. Headache-related symptoms were dominated by phonophotophobia, followed by nausea and vomiting. Almost all migraine sufferers were self-medicating, and very few were under the care of a doctor. First-line analgesics and NSAIDs were the mainstay of treatment.
 
</p></abstract><kwd-group><kwd>Migraine</kwd><kwd> Clinic</kwd><kwd> Therapeutics</kwd><kwd> Brazzaville</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Migraine is the most common primary headache [<xref ref-type="bibr" rid="scirp.131517-ref1">1</xref>] , causing significant disability. It is characterized by paroxysmal headache attacks, sometimes associated with nausea, vomiting, phonophobia or photophobia [<xref ref-type="bibr" rid="scirp.131517-ref2">2</xref>] . There are two types of migraine: migraine without aura and migraine with aura, with aura referring to the transient neurological manifestations that precede the migraine attack [<xref ref-type="bibr" rid="scirp.131517-ref3">3</xref>] . Diagnosis is essentially clinical, according to criteria laid down by the International Headache Association (IHS) [<xref ref-type="bibr" rid="scirp.131517-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref4">4</xref>] .</p><p>It is a major public health problem, with a global prevalence estimated at 11.6% in 2009 [<xref ref-type="bibr" rid="scirp.131517-ref5">5</xref>] , and an African prevalence of 10.4% [<xref ref-type="bibr" rid="scirp.131517-ref6">6</xref>] . In the Global Burden of Disease Survey, published in 2010, migraine was ranked as the third most common disorder and the seventh leading cause of disability worldwide [<xref ref-type="bibr" rid="scirp.131517-ref7">7</xref>] . In 2015, it was ranked as the third leading cause of disability in people under 50 [<xref ref-type="bibr" rid="scirp.131517-ref8">8</xref>] . This ranking is obviously linked not only to its high prevalence, but also to its considerable socio-economic impact [<xref ref-type="bibr" rid="scirp.131517-ref9">9</xref>] . The World Health Organization (WHO) also ranks it among the twenty most disabling conditions [<xref ref-type="bibr" rid="scirp.131517-ref10">10</xref>] . In the Republic of Congo, although migraine is a frequent reason for neurology consultations, with a prevalence of 11.3% in Brazzaville, there is as yet little data in the literature on the epidemiological, clinical and therapeutic profiles of migraine sufferers [<xref ref-type="bibr" rid="scirp.131517-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref12">12</xref>] .</p><p>As migraine pathology is under-documented in our context, and does not allow practitioners to have any hindsight on the quality of the follow-up and management of the subjects concerned, we proposed, through this work, to contribute to the state of the art and to the improvement of the management of this condition in the Republic of Congo.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>We conducted a door-to-door cross-sectional study from May 1<sup>st</sup> to July 1<sup>st</sup> 2018 in the city of Brazzaville.</p><p>Brazzaville is the political and administrative capital of the Congo. It is located on the right bank of the Congo River, and extends over 30 kilometers. It covers an area of around 11,500 hectares [<xref ref-type="bibr" rid="scirp.131517-ref13">13</xref>] . The city of Brazzaville is bounded to the north by the sub-prefecture of Ign&#233;, to the south by the sub-prefecture of Goma Ts&#233;-Ts&#233;, to the east by the Congo River, and to the west by the sub-prefecture of Mayama.</p><p>The city of Brazzaville comprises nine (9) arrondissements, subdivided into neighborhoods, zones and blocks. There are 87 districts, 434 zones and 3509 blocks [<xref ref-type="bibr" rid="scirp.131517-ref14">14</xref>] . In 2017, the population of Brazzaville was estimated at 1.838.348 [<xref ref-type="bibr" rid="scirp.131517-ref15">15</xref>] .</p><p>The work concerned all the inhabitants of the city of Brazzaville. A door-to-door survey was carried out, targeting headache sufferers. All subjects over 18 years of age who had clearly expressed their consent were included. Subjects with considerable cognitive or physical deficits that prevented them from answering the questionnaire, as well as those who refused to answer the questionnaire or answered only partially, were not taken into account.</p><p>Cluster random sampling was used to determine the sample size representative of the study population. Based on the Schwartz formula described below, the sample size was estimated at 864 subjects.</p><p>Schwartz formula</p><p>N = Z 2 P Q / I 2</p><p>with:</p><p>N: sample size.</p><p>Z: confidence level according to normal distribution (Z = 1.96 for a 95% confidence level).</p><p>P: the proportion of migraine sufferers in the general population in Africa (P = 10%).</p><p>Q = 1 − P and I: the 2% margin of error.</p><p>To determine the sample size (Y) in each Brazzaville arrondissement, the population of each arrondissement was weighted according to the percentage (X) of the population of each arrondissement in relation to the population of the city of Brazzaville. X = P arrondissement &#215; 100/P Brazzaville</p><p>Y = X &#215; P estimated/100 (P estimated = 864).</p><p>The survey was based on a questionnaire designed by us. The form explored socio-demographic characteristics, IHS diagnostic criteria for migraine, treatments taken during attacks and medical follow-up. The degree of disability due to migraine was determined using the MIDAS (Migraine Disability Assessment Scale) questionnaire [<xref ref-type="bibr" rid="scirp.131517-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref17">17</xref>] .</p><p>The survey was carried out by students at the end of their training in general medicine. The interviewers went door-to-door in all the districts of Brazzaville to fill in the questionnaire.</p><p>For each subject interviewed, questioning about headaches began with the question: “Do you often suffer from headaches?” if yes, the interview continued with the diagnostic criteria for migraine, if no, the interview ended.</p><p>The HIT-6 scale and MIDAS score were completed for all chronic headache sufferers.</p><p>Confirmatory diagnosis of migraine cases was made by two neurologists in accordance with ICHD 3 criteria.</p><p>Statistical analysis was performed using SPSS 22.0 for MAC. Numbers were compared using Pearson’s Chi-2 test, and means were compared using Student’s t-test.</p></sec><sec id="s3"><title>3. Results</title><p>Of the 1017 subjects interviewed in this study, 115 (39.9%) had migraine, including 73 women (63.47%) and 42 men (36.52%). The sex ratio was 0.57.</p><p>In the group of migraine sufferers, the number of cases of definite migraine was 61 (53%) and that of probable migraine 54 (47%).</p><p>The mean age at onset of migraine was 26.1 &#177; 10.3 years for all migraine sufferers. The median duration of the disease was 6.1 years, with an interquartile range of 3.3 to 10.9 years.</p><p>Subjects with definite migraine had a mean age at onset of 24.8 &#177; 9.8 years. This compares with 27.7 &#177; 10.8 years for probable migraine sufferers. The median values for length of illness were 7.6 and 5.3 years, respectively for definite and probable migraine sufferers.</p><p>Seventy (60.9%) of the migraine sufferers had a relative suffering from headaches.</p><p>For 81 migraine sufferers (70.43%), stress was the trigger for the migraine attack (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The frequency of attacks was weekly and monthly in 30 (26.1%) and 19 (16.5%) cases respectively. The location of the migraine was unilateral in 38% of cases and tilted in 24.3%. The intensity of the attack was described as moderate and severe in 41.7% and 57.4% of subjects respectively. Phonophobia/photophobia accompanied the migraine in 65.2% of cases (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical features</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >CHARACTERISTICS</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >HEADQUARTERS</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Unilateral</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >38.3</td></tr><tr><td align="center" valign="middle" >Rocking</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >24.3</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >46.1</td></tr><tr><td align="center" valign="middle" >Type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pulsatile</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >75.7</td></tr><tr><td align="center" valign="middle" >Burning</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >08.7</td></tr><tr><td align="center" valign="middle" >In the vice</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >17.4</td></tr><tr><td align="center" valign="middle" >Weightlessness</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >20.9</td></tr><tr><td align="center" valign="middle" >Crushing</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >01.7</td></tr><tr><td align="center" valign="middle" >Electrical discharge</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >02.6</td></tr><tr><td align="center" valign="middle" >Stab wound</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >02.6</td></tr><tr><td align="center" valign="middle" >Intensity</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Lightweight</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >00.9</td></tr><tr><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >41.7</td></tr><tr><td align="center" valign="middle" >Severe</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >57.4</td></tr><tr><td align="center" valign="middle" >Evolutionary mode</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Criticism</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >87.8</td></tr><tr><td align="center" valign="middle" >Continuous</td><td align="center" valign="middle" >014</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >Duration and frequency of seizures</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Duration (4 - 72 h)</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >87.0</td></tr><tr><td align="center" valign="middle" >Frequency of crises</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Not specified</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Daily newspaper</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >03.5</td></tr><tr><td align="center" valign="middle" >Weekly</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >26.1</td></tr><tr><td align="center" valign="middle" >Monthly</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >16.5</td></tr><tr><td align="center" valign="middle" >Irregular</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >53.9</td></tr><tr><td align="center" valign="middle" >Aggravating factors</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >64.3</td></tr><tr><td align="center" valign="middle" >Nausea</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >25.2</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >05</td><td align="center" valign="middle" >04.3</td></tr><tr><td align="center" valign="middle" >Phonophotophobia</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >65.2</td></tr></tbody></table></table-wrap><p>49 of the migraine sufferers (42.6%) had an aura. Of these, 38 (77.55%) had ophthalmic aura and 8 (16.33%) had multiple aura (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>The clinical characteristics of patients according to certain and probable migraine types are presented in <xref ref-type="table" rid="table2">Table 2</xref>. The clinical characteristics of patients according to the presence of aura are presented in <xref ref-type="table" rid="table3">Table 3</xref>.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical characteristics by migraine type</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >FEATURES</th><th align="center" valign="middle"  colspan="2"  >DEFINITE MIGRAINE (n = 61)</th><th align="center" valign="middle"  colspan="2"  >PROBABLE MIGRAINE (n = 54)</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Headquarters</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Lateral</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >32.8</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >44.4</td><td align="center" valign="middle" >0.199</td></tr><tr><td align="center" valign="middle" >Rocker</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >34.4</td><td align="center" valign="middle" >07</td><td align="center" valign="middle" >13.0</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >42.6</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >0.428</td></tr><tr><td align="center" valign="middle" >Type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pulsatile</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >75.4</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >75.9</td><td align="center" valign="middle" >0.949</td></tr><tr><td align="center" valign="middle" >Burn</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >06.6</td><td align="center" valign="middle" >06</td><td align="center" valign="middle" >11.1</td><td align="center" valign="middle" >0.387</td></tr><tr><td align="center" valign="middle" >In the vice</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >24.6</td><td align="center" valign="middle" >05</td><td align="center" valign="middle" >09.3</td><td align="center" valign="middle" >0.030</td></tr><tr><td align="center" valign="middle" >Gravity</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >19.7</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >22.2</td><td align="center" valign="middle" >0.737</td></tr><tr><td align="center" valign="middle" >Shredding</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.6</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.9</td><td align="center" valign="middle" >0.931</td></tr><tr><td align="center" valign="middle" >Electrical discharge</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >05.6</td><td align="center" valign="middle" >0.062</td></tr><tr><td align="center" valign="middle" >Stabbing</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.6</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >03.7</td><td align="center" valign="middle" >0.488</td></tr><tr><td align="center" valign="middle" >Intensity</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.156</td></tr><tr><td align="center" valign="middle" >Slight</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >36.1</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >48.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Severe</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >63.9</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Scalable mode</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.050</td></tr><tr><td align="center" valign="middle" >Review</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >93.4</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >81.5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Continuous</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >06.6</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >18.5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Seizure duration</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >98.4</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >74.1</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Seizure frequency</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.208</td></tr><tr><td align="center" valign="middle" >Daily</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >6.6</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Weekly</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >27.9</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >24.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Monthly</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >18.0</td><td align="center" valign="middle" >08</td><td align="center" valign="middle" >14.8</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Irregular</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >47.5</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >61.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Aggravating factors</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >70.5</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >57.4</td><td align="center" valign="middle" >0.144</td></tr><tr><td align="center" valign="middle" >Nausea</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >41.0</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >07.4</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >06.6</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.9</td><td align="center" valign="middle" >0.217</td></tr><tr><td align="center" valign="middle" >Phonophotophobia</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >80.3</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >48.1</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Clinical features according to presence of aura</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Features</th><th align="center" valign="middle"  colspan="2"  >Migraine With Aura (n = 49)</th><th align="center" valign="middle"  colspan="2"  >Migraine Without Aura (n = 66)</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Definite migraine</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >65.3</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >43.9</td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" >Migraine probable</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >34.7</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >56.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Headquarters</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Unilateral</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >38.8</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >37.9</td><td align="center" valign="middle" >0.922</td></tr><tr><td align="center" valign="middle" >Rocker</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >26.5</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >22.7</td><td align="center" valign="middle" >0.638</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >38.8</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >51.5</td><td align="center" valign="middle" >0.175</td></tr><tr><td align="center" valign="middle" >Type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pulsatile</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >69.4</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >80.3</td><td align="center" valign="middle" >0.177</td></tr><tr><td align="center" valign="middle" >Burn</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >04.1</td><td align="center" valign="middle" >08</td><td align="center" valign="middle" >12.1</td><td align="center" valign="middle" >0.185</td></tr><tr><td align="center" valign="middle" >In the vice</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >26.5</td><td align="center" valign="middle" >07</td><td align="center" valign="middle" >10.6</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle" >Gravity</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >24.5</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.2</td><td align="center" valign="middle" >0.410</td></tr><tr><td align="center" valign="middle" >Shredding</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >02.0</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.5</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >Electrical discharge</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >04.1</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.5</td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >Stabbing</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >04.1</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.5</td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >Intensity</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >Slight</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >01.5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >42.9</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >40.9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Severe</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >57.1</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >57.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Scalable mode</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.578</td></tr><tr><td align="center" valign="middle" >Review</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >89.8</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >89.8</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Continuous</td><td align="center" valign="middle" >05</td><td align="center" valign="middle" >10.2</td><td align="center" valign="middle" >05</td><td align="center" valign="middle" >10.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Seizure duration</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >89.8</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >84.8</td><td align="center" valign="middle" >0.436</td></tr><tr><td align="center" valign="middle" >Seizure frequency</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.141</td></tr><tr><td align="center" valign="middle" >Daily</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >04.1</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >03.0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Weekly</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >36.7</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Monthly</td><td align="center" valign="middle" >07</td><td align="center" valign="middle" >14.3</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Irregular</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >44.9</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >60.6</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>The MIDAS score values for characterizing seizure-related disability are shown in <xref ref-type="table" rid="table4">Table 4</xref>.</p><p>One hundred and eight subjects were receiving treatment. Of these, 106 (98.1%) were taking medication. Eleven (10.2%) had received a medical prescription, and ninety-seven (89.8%) were self-medicating. Five and three subjects were under the care of a general practitioner and a neurologist respectively. The different groups of drugs used in seizure management are shown in <xref ref-type="table" rid="table5">Table 5</xref>.</p></sec><sec id="s4"><title>4. Discussion</title><p>On the basis of the ICHD-3 criteria, 115 of the 1017 people surveyed were diagnosed as suffering from migraine. The majority were women (63.5% women, 36.5% men). The female predominance of migraine has been extensively described in the literature [<xref ref-type="bibr" rid="scirp.131517-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref20">20</xref>] . It may be explained by hormonal variations during the menstrual cycle and pregnancy, and by a genetic predisposition [<xref ref-type="bibr" rid="scirp.131517-ref21">21</xref>] .</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of all migraine sufferers by MIDAS</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >MIDAS grades</th><th align="center" valign="middle" >Employees (n)</th><th align="center" valign="middle" >Percentages (%)</th></tr></thead><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >30.26</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >31.31</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >18.26</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >12.17</td></tr><tr><td align="center" valign="middle" >MIDAS grouping</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Grades 1 and 2</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >69.56</td></tr><tr><td align="center" valign="middle" >Grades 3 and 4</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >30.44</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Management</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >TERMS AND CONDITIONS</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Type of treatment (N = 108)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Medicinal products</td><td align="center" valign="middle" >106</td><td align="center" valign="middle" >98.1</td></tr><tr><td align="center" valign="middle" >Non-drugs</td><td align="center" valign="middle" >002</td><td align="center" valign="middle" >01.9</td></tr><tr><td align="center" valign="middle" >Drugs used (N = 108)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Analgesics</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >65.7</td></tr><tr><td align="center" valign="middle" >NSAIDS</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >62.0</td></tr><tr><td align="center" valign="middle" >Triptans</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >00.9</td></tr><tr><td align="center" valign="middle" >Antiepileptics</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >00.9</td></tr><tr><td align="center" valign="middle" >Antidepressants</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >02.8</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >13.9</td></tr></tbody></table></table-wrap><p>The mean age at disease onset was 26.1 &#177; 10.3 years. This result is in line with the literature. Indeed, subjects in their twenties and thirties are the most affected, with peak frequency between the ages of 30 and 39 [<xref ref-type="bibr" rid="scirp.131517-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref23">23</xref>] .</p><p>Stress was the most frequent trigger (81%), followed by hormonal factors (67%). The predominance of psychological triggers, including stress, is mentioned in several studies. In a study in Senegal, psychological factors were incriminated in 76% of subjects. Climatic and hormonal factors followed in 63% and 21% of cases respectively [<xref ref-type="bibr" rid="scirp.131517-ref24">24</xref>] . Similarly, in France, a study associated the onset of migraines with fear, anxiety and anger in 55.6%, 57.9% and 55.3% of people respectively. Hormonal factors affected 29.9% of women [<xref ref-type="bibr" rid="scirp.131517-ref25">25</xref>] .</p><p>The relationship between a family history of migraine and its onset has been proven in numerous studies. McGregor, for example, states that the risk of a migraine sufferer having a parent with migraine is 40%. If both parents are affected, the risk is 75% [<xref ref-type="bibr" rid="scirp.131517-ref26">26</xref>] . Another author estimates that this risk is multiplied by 1.9 for migraine without aura and by 4 for migraine with aura [<xref ref-type="bibr" rid="scirp.131517-ref27">27</xref>] . In line with these observations, 60.9% of the migraine sufferers we interviewed had a first-degree relative with migraine.</p><p>Classically, migraine without aura is more frequent than migraine with aura [<xref ref-type="bibr" rid="scirp.131517-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref23">23</xref>] . The same observation was made in our study. There were 57.4% cases of migraine without aura and 42.6% with aura. In the 49 subjects who had migraine with aura, ophthalmic aura was the predominant type (40% of all migraineurs and). These results are superimposed on those of Streel et al. in Belgium, who reported a preeminence of visual manifestations of migraine aura, with an estimated frequency of 40.8% in their series [<xref ref-type="bibr" rid="scirp.131517-ref28">28</xref>] . Among the symptoms accompanying the attack, the most frequent were phonophotophobia and vomiting, respectively 62.5% and 04.3% of cases. In a study carried out in PIKINE, Senegal, photophobia and phonophobia were the most frequent accompanying signs, in 58% and 70% of cases respectively [<xref ref-type="bibr" rid="scirp.131517-ref24">24</xref>] . Similar results have been reported in other studies [<xref ref-type="bibr" rid="scirp.131517-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref30">30</xref>] .</p><p>Disability due to the disease, as assessed by the MIDAS score, also reflects the severity of the attacks. In the population of migraine sufferers we surveyed, 35% were classified as MIDAS grade III to IV and 80% as grade I to II. These results are close to those reported in an international survey, the Global Migraine and Zolmitriptan Evaluation (MAZE). According to this study, the percentages of grade III and IV migraine sufferers were 47% in England and 48% in Germany [<xref ref-type="bibr" rid="scirp.131517-ref31">31</xref>] .</p><p>One hundred and six of the 115 migraine sufferers were taking medication to treat their condition. Of these, only 8 (6.9% of migraine sufferers) had received a medical prescription, three of whom were under the care of a neurologist. The common practice of self-medication among migraine sufferers has been reported in several studies [<xref ref-type="bibr" rid="scirp.131517-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.131517-ref33">33</xref>] .</p><p>In the Congo, this practice is said to be partly facilitated by the widespread availability of street medicines. What’s more, according to a French study, the fact that patients consider migraine not to be a serious illness justifies the absence of recourse to a doctor [<xref ref-type="bibr" rid="scirp.131517-ref25">25</xref>] . The most commonly used medications were first-line analgesics (65.7%) and anti-inflammatories (62.03%). The use of triptans was very low, with only one case reported. A similar finding was made in an international study, which reported 3% to 19% of migraine sufferers followed up by a doctor who had a triptan-based treatment [<xref ref-type="bibr" rid="scirp.131517-ref31">31</xref>] . It should be noted that none of the migraine sufferers in our study was taking an ergot derivative.</p><p>Optimal monitoring of migraine medication requires the use of a migraine diary. Among other things, this tool can be used to record the total number of doses of medication taken per month, in order to identify non-compliance or overuse that could lead to chronic headaches [<xref ref-type="bibr" rid="scirp.131517-ref3">3</xref>] . It also helps to assess treatment efficacy. In our study, only two patients used a migraine diary. These patients were under the care of a neurologist. The low number of neurologists in Brazzaville, which has an estimated population of 1,838,348 inhabitants and a staff of 5 neurologists, 3 of whom share a public-private practice, may explain this.</p></sec><sec id="s5"><title>5. Conclusions</title><p>This study, carried out in the general population, shows that migraine is a frequent pathology in Brazzaville, affecting mainly women at an early age, and mostly without any warning aura.</p><p>Self-medication and lack of medical follow-up were the rule. First-line analgesics and NSAIDs were the mainstay of treatment, often purchased on the street. These facts underline the need to set up mass information programs on migraine pathology and the importance of medical follow-up, in order to contribute to efficient management.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Boubayi, M.L.H.D., Diatewa, J., Bandzouzi, P.E.G.S., Mpandzou, G.A., Ikora, H.S.O., Aloba, K.L.O. and Ossou-Nguiet, P.M. (2024) Clinical and Therapeutic Aspects of Migraine in Brazzaville. World Journal of Neuroscience, 14, 56-71. https://doi.org/10.4236/wjns.2024.141006</p></sec><sec id="s8"><title>Appendix 1</title><p>SURVEY FORM</p><p>Telephone number:</p><p>Survey date: /....../....../ /......./......../ /......../......./......./ Survey location: .................. Inclusion number: ...........</p><p> SOCIO-DEMOGRAPHIC IDENTIFICATION:</p><p>1) Age in years:</p><p>2) Sex: F M <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x5.png" xlink:type="simple"/></inline-formula></p><p>3) Profession:<inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x6.png" xlink:type="simple"/></inline-formula></p><p>(1-Public servant) (2-Private sector employee) (3-Informal activities) (4-Pupil/student) (5-No job) (6-Retired)</p><p>4) Working hours per day:</p><p>5) Overtime:</p><p>6) Level of education:</p><p>1 (1-Primary) (2-Secondary) (3-Higher) (4-No schooling)</p><p>7) Marital status:</p><p>(1-Married) (2-Single) (3-Couple) (4-Widowed) (5-Divorced)</p><p>8) Number of spouses:</p><p>9) Number of children:</p><p>10) Residence: Are you an owner <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x7.png" xlink:type="simple"/></inline-formula> or a tenant? <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x8.png" xlink:type="simple"/></inline-formula></p><p>11) Socio-economic level:</p><p>Very low 3 - 4 <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x9.png" xlink:type="simple"/></inline-formula> High 9 - 10 <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x10.png" xlink:type="simple"/></inline-formula></p><p>Low 5 - 6 <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x11.png" xlink:type="simple"/></inline-formula> Very high 11 - 12 <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x12.png" xlink:type="simple"/></inline-formula></p><p>Medium 7 - 8 <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x13.png" xlink:type="simple"/></inline-formula></p><p>12) Do you use: Alcohol <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x14.png" xlink:type="simple"/></inline-formula> Tobacco <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x14.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x15.png" xlink:type="simple"/></inline-formula> Other drugs <inline-formula><inline-graphic xlink:href="/html.scirp.org/file/6-1390739x14.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x15.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x16.png" xlink:type="simple"/></inline-formula></p><p>13) Are there any headache sufferers in your family? Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x17.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x17.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x18.png" xlink:type="simple"/></inline-formula></p><p>14) Do you often suffer from headaches? Yes<inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x19.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x19.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x20.png" xlink:type="simple"/></inline-formula></p><p>If yes:</p><p>15) How long have you suffered from headaches? Day <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x21.png" xlink:type="simple"/></inline-formula> Week <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x21.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x22.png" xlink:type="simple"/></inline-formula> Month <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x21.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x22.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x23.png" xlink:type="simple"/></inline-formula> Year <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x21.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x22.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x23.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x24.png" xlink:type="simple"/></inline-formula> If year, what is the estimated age of onset?…</p><p> CHARACTERISTICS OF CEPHALEA</p><p>1) Where is your pain located? One side <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x25.png" xlink:type="simple"/></inline-formula> The whole head <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x25.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x26.png" xlink:type="simple"/></inline-formula> One side then the other <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x25.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x26.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x27.png" xlink:type="simple"/></inline-formula></p><p>2) What does your pain feel like? It hits <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula> It burns <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula> It squeezes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x30.png" xlink:type="simple"/></inline-formula> It weighs <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x30.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x31.png" xlink:type="simple"/></inline-formula> It crushes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x30.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x31.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x32.png" xlink:type="simple"/></inline-formula> Like a shock <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x30.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x31.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x32.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x33.png" xlink:type="simple"/></inline-formula> Like a stab wound <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x28.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x29.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x30.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x31.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x32.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x33.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x34.png" xlink:type="simple"/></inline-formula></p><p>3) When you feel pain, how would you rate its intensity (VAS)? Slight <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x35.png" xlink:type="simple"/></inline-formula> Moderate <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x35.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x36.png" xlink:type="simple"/></inline-formula> Severe <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x35.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x36.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x37.png" xlink:type="simple"/></inline-formula> Very severe <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x35.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x36.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x37.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x38.png" xlink:type="simple"/></inline-formula></p><p>4) How does your headache evolve? Per attack <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x39.png" xlink:type="simple"/></inline-formula> Ongoing <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x39.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x40.png" xlink:type="simple"/></inline-formula></p><p>5) If an attack, does it last between 4 and 72 hours? Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x41.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x41.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x42.png" xlink:type="simple"/></inline-formula></p><p>6) If you have an attack, how often do you have them? Daily <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x43.png" xlink:type="simple"/></inline-formula> Weekly <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x43.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x44.png" xlink:type="simple"/></inline-formula> Monthly <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x43.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x44.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x45.png" xlink:type="simple"/></inline-formula> Irregular <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x43.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x44.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x45.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x46.png" xlink:type="simple"/></inline-formula></p><p>7) Is your headache aggravated by routine physical activities (walking, climbing stairs) Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x47.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x47.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x48.png" xlink:type="simple"/></inline-formula></p><p>8) Is your headache accompanied by: The urge to vomit <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x49.png" xlink:type="simple"/></inline-formula> Vomiting <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x49.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x50.png" xlink:type="simple"/></inline-formula> Gene to light <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x49.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x50.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x51.png" xlink:type="simple"/></inline-formula> Gene to noise <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x49.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x50.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x51.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x52.png" xlink:type="simple"/></inline-formula></p><p>9) Have you had at least five seizures meeting criteria 5 and 8? Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x53.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x53.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x54.png" xlink:type="simple"/></inline-formula></p><p>10) Is your headache preceded by or accompanied by (aura):</p><p>Visual disturbances: Bright spots <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x55.png" xlink:type="simple"/></inline-formula> Flashes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x55.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x56.png" xlink:type="simple"/></inline-formula> Broken lines <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x55.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x56.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x57.png" xlink:type="simple"/></inline-formula></p><p>Visual blur <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x58.png" xlink:type="simple"/></inline-formula> Blind zone <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x58.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x59.png" xlink:type="simple"/></inline-formula> Visual hallucinations/distortion <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x58.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x59.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x60.png" xlink:type="simple"/></inline-formula></p><p>Sensory or motor disorders: tingling, numbness, weakness of a limb Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x61.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x61.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x62.png" xlink:type="simple"/></inline-formula></p><p>Balance disorders, vertigo, loss of consciousness: Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x63.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x63.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x64.png" xlink:type="simple"/></inline-formula></p><p>11) At least one aura symptom develops progressively over ≥5 minutes and/or the various aura symptoms occur successively</p><p>Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x65.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x65.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x66.png" xlink:type="simple"/></inline-formula></p><p>12) Duration of each aura symptom 5 - 60 minutes: Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x67.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x67.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x68.png" xlink:type="simple"/></inline-formula></p><p>13) At least one aura symptom is unilateral: Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x69.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x69.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x70.png" xlink:type="simple"/></inline-formula></p><p>14) Aura accompanied or followed within 60 minutes by headache</p><p>Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x71.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x71.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x72.png" xlink:type="simple"/></inline-formula></p><p>15) Factors triggering seizures:</p><p>Stress: <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x73.png" xlink:type="simple"/></inline-formula></p><p>Hormonal factors: rule <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x74.png" xlink:type="simple"/></inline-formula> Oral contraception <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x74.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x75.png" xlink:type="simple"/></inline-formula></p><p>Dietary factors: alcohol <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x76.png" xlink:type="simple"/></inline-formula> chocolate <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x76.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x77.png" xlink:type="simple"/></inline-formula> other..................... <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x76.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x77.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x78.png" xlink:type="simple"/></inline-formula></p><p>-Sensory factors: Flashing light <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x79.png" xlink:type="simple"/></inline-formula> Striped d&#233;cor <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x79.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x80.png" xlink:type="simple"/></inline-formula> Noise <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x79.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x80.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x81.png" xlink:type="simple"/></inline-formula> Odor <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x79.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x80.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x81.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x82.png" xlink:type="simple"/></inline-formula></p><p>Other: sleeping too long <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x83.png" xlink:type="simple"/></inline-formula> hypoglycemia <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x83.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x84.png" xlink:type="simple"/></inline-formula> Heat <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x83.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x84.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x85.png" xlink:type="simple"/></inline-formula></p><p>16) Treatment of headache: ............................................................</p><p>17) Medical follow-up: General practitioner <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x86.png" xlink:type="simple"/></inline-formula> Specialist <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x86.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x87.png" xlink:type="simple"/></inline-formula></p><p>18) Use of a migraine diary: Yes <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x88.png" xlink:type="simple"/></inline-formula> No <inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x88.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="//html.scirp.org/file/6-1390739x89.png" xlink:type="simple"/></inline-formula></p><p> EVALUATION OF LOSS OF PRODUCTIVITY (MIDAS)</p><p> HIT-6 scale</p></sec><sec id="s9"><title>Appendix 2: Migraine Diary</title><p>:mild, ++ moderate, +++ severe, CT.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.131517-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Headache Classification Committee of the International Headache Society (IHS) (2013) Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition (Beta Version). Cephalalgia, 33, 629-808. https://doi.org/10.1177/0333102413485658</mixed-citation></ref><ref id="scirp.131517-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Dodick, D.W. (2018) Migraine. The Lancet Journal, 391, 1315-1330.  
https://doi.org/10.1016/S0140-6736(18)30478-1</mixed-citation></ref><ref id="scirp.131517-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, M.A., Haddad, M., Kouassi, B., Ouhabi, H. and Serrie, A. (2016) Formalized Consensus: Clinical Practice Recommendation for the Management of Migraine in the African Adult Patients. The Pan African Medical Journal, 24, Article 81.</mixed-citation></ref><ref id="scirp.131517-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia, 38, 1-211. https://doi.org/10.1177/0333102417738202</mixed-citation></ref><ref id="scirp.131517-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bigal, M.E. and Lipton R.B. (2009) The Epidemiology, Burden, and Comorbidities of Migraine. Neurologic Clinics, 27, 321-334.  
https://doi.org/10.1016/j.ncl.2008.11.011</mixed-citation></ref><ref id="scirp.131517-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Woldeamanuel Y.W. and Cowan, R.P. (2016) Migraine Affects 1 in 10 People Worldwide Featuring Recent Rise: A Systematic Review and Meta-Analysis of Community-Based Studies Involving 6 Million Participants. Journal of the Neurological Sciences, 372, 307-315. https://doi.org/10.1016/j.jns.2016.11.071</mixed-citation></ref><ref id="scirp.131517-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., et al. (2012) Years Lived with Disability (YLDs) for 1160 Sequelae of 289 Diseases and Injuries 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2</mixed-citation></ref><ref id="scirp.131517-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Steiner, T.J., Stovner, L.J. and Vos, T. (2016) GBD 2015: Migraine Is the Third Cause of Disability in under 50s. The Journal of Headache and Pain, 17, Article No. 104. https://doi.org/10.1186/s10194-016-0699-5</mixed-citation></ref><ref id="scirp.131517-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lanteri-Minet, M., Valade, D., Geraud, G., Chautard, M.H. and Lucas, C. (2005) Migraine and Propable Migraine—Results of FRAMIG 3, a French Nationwide Survey Carried out According to the 2004 IHS Classification. Cephalalgia, 25, 1146-1158. https://doi.org/10.1111/j.1468-2982.2005.00977.x</mixed-citation></ref><ref id="scirp.131517-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Demarin, V. and Vukovi&amp;#263;, V. (2008) Migraine—A Burden for the Individual and the Society. Acta Medica Croatica, 62, 137-140.</mixed-citation></ref><ref id="scirp.131517-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ossou-Nguiet, P.M., Gnonlonfoun, D., Matali, E., Obondzo-Aloba, K., Nguienia, D., Banzouzi, L., et al. (2015) Drug Overuse and Chronic Headaches in Brazzaville: Patients Profile and Therapeutic Itinerary. Cephalalgia, 35, Article No. 106.</mixed-citation></ref><ref id="scirp.131517-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ossou-Nguiet, P., Mpandzou, G.A., Carole, T.B., Diatewa, J.E., Ongoly-Ikora, H.S., Sounga-Bandzouzi, P.E., et al. (2019) Prevalence and Epidemiological Profile of Migraine in the City of Brazzaville. Revue Neurologique, 175, S119-S120. 
https://doi.org/10.1016/j.neurol.2019.01.316</mixed-citation></ref><ref id="scirp.131517-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kube Technologie (2017) Commune de Brazzaville, Congo: Les arrondissements.  
http:www.brazzaville.cg/fr</mixed-citation></ref><ref id="scirp.131517-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Opo, U.F. (2009) Qualité des eaux souterraines des quartiers périphériques de l’arrondissement 1 de Brazzaville. 115.</mixed-citation></ref><ref id="scirp.131517-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Atlas of World Populations and Countries (2017).  
http:www.populationdata.net/pays/congo</mixed-citation></ref><ref id="scirp.131517-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Radat, F. and Lanteri-Minet, M. (2008) Evaluation of Migraine. La Revue du Praticien, 58, 616-624.</mixed-citation></ref><ref id="scirp.131517-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, W.F., Lipton, R.B., Kolodnerb, K.B., Sawyere, J., Leeb, C. and Liberman, J.N. (2000) Validity of the Migraine Disability Assessment (MIDAS) Score in Comparison to a Diary-Based Measure in a Population Sample of Migraine Sufferers. Pain, 88, 41-52. https://doi.org/10.1016/S0304-3959(00)00305-5</mixed-citation></ref><ref id="scirp.131517-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mbewe, E., Zairemthiama, P., Yeh, H.-H., Paul, R., Birbeck, G.L. and Steiner, T.J. (2015) The Epidemiology of Primary Headache Disorders in Zambia: A Population-Based Door-to-Door Survey. The Journal of Headache and Pain, 16, Article No. 30. https://doi.org/10.1186/s10194-015-0515-7</mixed-citation></ref><ref id="scirp.131517-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bada, A.R. (2005) Epidemiological and Clinical Study of Headaches in the District of Bamako. PhD Thesis, Bamako, 112 p.</mixed-citation></ref><ref id="scirp.131517-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">El-Sherbiny, N.A., Masoud, M., Shalaby, N.M. and Shehata, H.S. (2015) Prevalence of Primary Headache Disorders in Fayoum Governorate, Egypt. The Journal of Headache and Pain, 16, Article No. 85. https://doi.org/10.1186/s10194-015-0569-6</mixed-citation></ref><ref id="scirp.131517-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, W.F., Wood, C., Reed, M.L., et al. (2008) Cumulative Lifetime Migraine Incidence in Women and Men. Cephalalgia, 28, 1170-1178. 
https://doi.org/10.1111/j.1468-2982.2008.01666.x</mixed-citation></ref><ref id="scirp.131517-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Burch, R., Rizzoli, P. and Loder, E. (2018) The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends from Government Health Studies. Headache, 58, 496-505. https://doi.org/10.1111/head.13281</mixed-citation></ref><ref id="scirp.131517-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Schroeder, R.A., Brandes, J., Buse, D.C., Calhoun, A., Eikermann-Haerter, K., Golden, K., et al. (2018) Sex and Gender Differences in Migraine—Evaluating Knowledge Gaps. Journal of Women’s Health, 27, 965-973. 
https://doi.org/10.1089/jwh.2018.7274</mixed-citation></ref><ref id="scirp.131517-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Fall, M., Léye, Y., Ndiaye, N., Seck, S.N., Niang, S., Niass, A., et al. (2014) Epidemiological Aspects and Diagnostic Headaches. About a Hundred Series of Cases Followed in Pikine National Hospital Center in Dakar. Dakar Medical, 59, 144-149. 
https://doi.org/10.1016/j.neurol.2012.07.022</mixed-citation></ref><ref id="scirp.131517-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lanteri-Minet, M., Valade, D., Geraud, G., Lucas, C. and Donnet, A. (2013) Diagnostic and Therapeutic Management of Migraine in Adults and Children. Revue Neurologique, 169, 14-29. https://doi.org/10.1016/j.neurol.2012.07.022</mixed-citation></ref><ref id="scirp.131517-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">MacGregor, E.A. (2017) Migraine Clinic. American College of Physicians. Annals of Internal Medicine, 50-64. https://doi.org/10.7326/AITC201704040</mixed-citation></ref><ref id="scirp.131517-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Russell, M.B., Iselius, L. and Olesen, J. (1996) Migraine without Aura and Migraine with aura Are Inherited Disorders. Cephalalgia, 16, 305-309. 
https://doi.org/10.1046/j.1468-2982.1996.1605305.x</mixed-citation></ref><ref id="scirp.131517-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Streel, S., Donneau, A.-F., Hoge, A., Albert, A., Schoenen, J. and Guillaume, M. (2015) One-Year Prevalence of Migraine Using a Validated Extended French Version of the ID Migraine TM: A Belgian Population-Based Study. Revue Neurologique, 171, 707-714. https://doi.org/10.1016/j.neurol.2015.04.009</mixed-citation></ref><ref id="scirp.131517-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Maiga, Y., Souma&amp;#239;la, B., Cissoko, L.N., Sangaré, M., Diallo, S.H., Diallo, S., et al. (2017) Epidemiology of Migraine among Students in Mali. eNeurologicalSci, 7, 32-36. https://doi.org/10.1016/j.ensci.2017.04.001</mixed-citation></ref><ref id="scirp.131517-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">&amp;#214;zdemir, G., Aygül, R., Demir, R., &amp;#214;zel, L., Ertekin, A. and Ulv&amp;#239;, H. (2014) Migraine Prevalence, Disability, and Sociodemographic Properties in the Eastern Region of Turkey: A Population-Based Door-to-Door Survey. Turkish Journal of Medical Sciences, 44, 624-629.</mixed-citation></ref><ref id="scirp.131517-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">MacGregor, E.A., Brandes, J. and Eikermann, A. (2003) Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation Survey. HEADACH, 43, 19-26. https://doi.org/10.1046/j.1526-4610.2003.03004.x</mixed-citation></ref><ref id="scirp.131517-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Chua, A.L., Del Rio, M.S. and Silberstein, S. (2017) Migraine. In: Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier, Amsterdam, 1-13.  
https://doi.org/10.1016/B978-0-12-809324-5.03097-2</mixed-citation></ref><ref id="scirp.131517-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, W.F., Lipton, R.B., Celentano, D.D. and Reed, M.L. (1992) Prevalence of Migraine Headache in the United States. Relation to Age, Income, Race, and Other Sociodemographic Factors. JAMA, 267, 64-69. 
https://doi.org/10.1001/jama.1992.03480010072027</mixed-citation></ref></ref-list></back></article>